共 35 条
Two-Year Outcomes After Minimally Invasive Surfactant Therapy in Preterm Infants Follow-Up of the OPTIMIST-A Randomized Clinical Trial
被引:9
作者:
Dargaville, Peter A.
[1
,2
]
Kamlin, C. Omar F.
[3
,4
]
Orsini, Francesca
[5
]
Wang, Xiaofang
[5
]
De Paoli, Antonio G.
[2
]
Kanmaz Kutman, H. Gozde
[6
]
Cetinkaya, Merih
[7
]
Kornhauser-Cerar, Lilijana
[8
]
Derrick, Matthew
[9
]
Ozkan, Hilal
[10
]
Hulzebos, Christian V.
[11
]
Schmoelzer, Georg M.
[12
]
Aiyappan, Ajit
[13
]
Lemyre, Brigitte
[14
]
Kuo, Sheree
[15
]
Rajadurai, Victor S.
[16
]
O'Shea, Joyce
[17
]
Biniwale, Manoj
[18
,19
]
Ramanathan, Rangasamy
[18
,19
]
Kushnir, Alla
[20
]
Bader, David
[21
]
Thomas, Mark R.
[22
]
Chakraborty, Mallinath
[23
]
Buksh, Mariam J.
[24
]
Bhatia, Risha
[25
]
Sullivan, Carol L.
[26
]
Shinwell, Eric S.
[27
]
Dyson, Amanda
[28
]
Barker, David P.
[29
]
Kugelman, Amir
[30
]
Donovan, Tim J.
[31
]
Goss, Kevin C. W.
[32
]
Tauscher, Markus K.
[33
]
Murthy, Vadivelam
[34
]
Ali, Sanoj K. M.
[35
]
Clark, Howard W.
[36
]
Soll, Roger F.
[37
]
Johnson, Samantha
[38
]
Cheong, Jeanie L. Y.
[3
,4
,39
]
Carlin, John B.
[5
,40
]
Davis, Peter G.
[3
,4
]
机构:
[1] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia
[2] Royal Hobart Hosp, Dept Paediat, Hobart, Tas, Australia
[3] Royal Hosp Women, Neonatal Serv, Melbourne, Vic, Australia
[4] Univ Melbourne, Dept Obstet & Gynaecol, Melbourne, Vic, Australia
[5] Murdoch Childrens Res Inst, Clin Epidemiol & Biostat Unit, Melbourne, Vic, Australia
[6] Zekai Tahir Burak Matern Teaching Hosp, Dept Neonatol, Ankara, Turkiye
[7] Istanbul Kanuni Sultan Suleyman Training & Res Ho, Div Neonatol, Dept Pediat, Istanbul, Turkiye
[8] Univ Med Ctr, Div Gynaecol & Obstet, Dept Perinatol, Ljubljana, Slovenia
[9] Northshore Univ Hlth Syst, Div Neonatol, Evanston, IL USA
[10] Uludag Univ, Div Neonatol, Dept Pediat, Fac Med, Bursa, Turkiye
[11] Univ Med Ctr Groningen, Div Neonatol, Beatrix Childrens Hosp, Groningen, Netherlands
[12] Univ Alberta, Div Neonatol, Dept Pediat, Edmonton, AB, Canada
[13] Mercy Hosp Women, Neonatal Serv, Heidelberg, Vic, Australia
[14] Ottawa Hosp, Dept Obstet Gynecol & Newborn Care, Ottawa, ON, Canada
[15] Kapiolani Med Ctr Women & Children, Dept Pediat, Honolulu, HI USA
[16] KK Womens & Childrens Hosp, Duke NUS Med Sch, Dept Neonatol, Singapore, Singapore
[17] Royal Hosp Children, Neonatal Unit, Glasgow, Lanark, Scotland
[18] Los Angeles Cty USC Med Ctr, Div Neonatol, Dept Pediat, Los Angeles, CA USA
[19] USC, Good Samaritan Hosp, Keck Sch Med, Los Angeles, CA USA
[20] Cooper Univ Hlth Care, Dept Pediat, Childrens Reg Hosp, Camden, NJ USA
[21] Technion, Dept Neonatol, Rappaport Fac Med, Bnai Zion Med Ctr, Haifa, Israel
[22] Chelsea & Westminster Hosp NHS Fdn Trust, Dept Neonatal Med, London, England
[23] Univ Hosp Wales, Reg Neonatal Intens Care Unit, Cardiff, Wales
[24] Auckland Hosp, Newborn Serv, Starship Child Hlth, Auckland, New Zealand
[25] Monash Childrens Hosp, Monash Newborn, Clayton, Vic, Australia
[26] Singleton Hosp, Dept Neonatol, Swansea, W Glam, Wales
[27] Bar Ilan Univ, Ziv Med Ctr, Dept Neonatol, Fac Med, Safed, Israel
[28] Canberra Hosp, Dept Neonatol, Centenary Hosp Women & Children, Woden, ACT, Australia
[29] Dunedin Publ Hosp, Neonatal Intens Care Unit, Dunedin, New Zealand
[30] Technion, Rappaport Fac Med, Dept Neonatol, Rambam Med Ctr, Haifa, Israel
[31] Royal Brisbane & Womens Hosp, Div Neonatol, Brisbane, Qld, Australia
[32] Princess Anne Hosp, Neonatal Intens Care Unit, Southampton, Hants, England
[33] Ascens St Vincent, Div Neonatol, Peyton Manning Childrens Hosp, Indianapolis, IN USA
[34] Royal London Hosp Barts Hlth NHS Fdn Trust, Neonatal Intens Care Ctr, London, England
[35] Sidra Med, Div Neonatol, Doha, Qatar
[36] UCL, Fac Populat Hlth Sci, Neonatol, EGA Inst Womens Hlth, London, England
[37] Univ Vermont, Larner Coll Med, Div Neonatal Perinatal Med, Burlington, VT 05405 USA
[38] Univ Leicester, Infant Mortal & Morbid Studies Res Grp, Dept Populat Hlth Sci, Leicester, Leics, England
[39] Murdoch Childrens Res Inst, Clin Sci, Melbourne, Vic, Australia
[40] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia
来源:
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
|
2023年
/
330卷
/
11期
基金:
英国医学研究理事会;
关键词:
CHRONIC LUNG-DISEASE;
RESPIRATORY OUTCOMES;
VENTILATION;
CHILDREN;
RATES;
AGE;
D O I:
10.1001/jama.2023.15694
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
IMPORTANCE The long-term effects of surfactant administration via a thin catheter (minimally invasive surfactant therapy [MIST]) in preterm infants with respiratory distress syndrome remain to be definitively clarified. OBJECTIVE To examine the effect of MIST on death or neurodevelopmental disability (NDD) at 2 years' corrected age. DESIGN, SETTING, AND PARTICIPANTS Follow-up study of a randomized clinical trial with blinding of clinicians and outcome assessors conducted in 33 tertiary-level neonatal intensive care units in 11 countries. The trial included 486 infants with a gestational age of 25 to 28 weeks supported with continuous positive airway pressure (CPAP). Collection of follow-up data at 2 years' corrected age was completed on December 9, 2022. INTERVENTIONS Infants assigned to MIST (n = 242) received exogenous surfactant (200 mg/kg poractant alfa) via a thin catheter; those assigned to the control group (n = 244) received sham treatment. MAIN OUTCOMES AND MEASURES The key secondary outcome of death or moderate to severe NDD was assessed at 2 years' corrected age. Other secondary outcomes included components of this composite outcome, as well as hospitalizations for respiratory illness and parent-reported wheezing or breathing difficulty in the first 2 years. RESULTS Among the 486 infants randomized, 453 had follow-up data available (median gestation, 27.3 weeks; 228 females [50.3%]); data on the key secondary outcome were available in 434 infants. Death or NDD occurred in 78 infants (36.3%) in the MIST group and 79 (36.1%) in the control group (risk difference, 0%[95% CI, -7.6% to 7.7%]; relative risk [RR], 1.0 [95% CI, 0.81-1.24]); components of this outcome did not differ significantly between groups. Secondary respiratory outcomes favored the MIST group. Hospitalization with respiratory illness occurred in 49 infants (25.1%) in the MIST group vs 78 (38.2%) in the control group (RR, 0.66 [95% CI, 0.54-0.81]) and parent-reported wheezing or breathing difficulty in 73 (40.6%) vs 104 (53.6%), respectively (RR, 0.76 [95% CI, 0.63-0.90]). CONCLUSIONS AND RELEVANCE In this follow-up study of a randomized clinical trial of preterm infants with respiratory distress syndrome supported with CPAP, MIST compared with sham treatment did not reduce the incidence of death or NDD by 2 years of age. However, infants who received MIST had lower rates of adverse respiratory outcomes during their first 2 years of life.
引用
收藏
页码:1054 / 1063
页数:10
相关论文